Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare ...

NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

Despite the drug – known as donanemab - being found to stall the deadly condition, its impact was not deemed worth the cost.

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...